Our current focus in oncology includes cancer stem cells as targets for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and triple negative breast cancer (TNBC).  Our lead program is in AML where our lead agent, ES-3000 reduces β-catenin. Wnt/β-catenin is a critical cancer stem cell survival pathway.

 

Acute myeloid leukemia (AML) is the most common acute leukemia...

Chronic myeloid leukemia (CML) is caused by...

Pancreatic cancer is the fourth...